Navigation Links
Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer

INGELHEIM, Germany and ST. JOSEPH, Mo., Oct. 26 /PRNewswire/ -- Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business. The acquisition, which includes products in the U.S., Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, significantly increases the size of Boehringer Ingelheim's companion animal and cattle portfolios and strengthens the company's position as a leading vaccine supplier. Terms of the deal were not disclosed. Products being acquired in Europe are still subject to approval by European anti-trust authorities.

"Boehringer Ingelheim and Fort Dodge share a strong commitment to innovation and this will continue to be the imperative basis of all our activities as we move forward," said Hubertus von Baumbach, Member of the Board of Managing Directors of Boehringer Ingelheim responsible for Finance and Animal Health. "With the closing of this deal, our attention now turns to ensuring a seamless integration of the highly committed teams of people as well as the transition of the product portfolio. We aim to jointly execute a robust business strategy that ensures the continued growth of our animal health business in the U.S. and globally by continuously providing innovation to our customers."

As part of the deal, Boehringer Ingelheim will acquire the Duramune® line of vaccines for dogs, the Fel-O-Vax® line of vaccines for cats, and the Rabvac® line of rabies vaccines manufactured and sold in the U.S., Canada and Australia. In addition, a portfolio of pet and equine pharmaceutical products currently sold in the U.S. is also included in the deal. The company will also acquire cattle vaccines in the U.S. and Canada including the Triangle®, Pyramid®, and Presponse® vaccine lines. Pharmaceutical products being acquired include Cydectin® (moxidectin) for cattle and sheep as well as Polyflex® (ampicillin sodium). The dairy portfolio includes the key brands Today® and Tomorrow®. Several Canadian swine vaccines are included in the acquisition as are some cattle vaccines sold in Europe and South Africa.

"The products included in this acquisition complement our already strong product lines and help to broaden our innovation base across more species and boost our global pipeline," said Prof. Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim. "We look forward to applying our innovative culture to the products included in this acquisition as well as to the research and discovery of new products that will continue to bring value to our customers and our business."

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of U.S. $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

About Boehringer Ingelheim Vetmedica, Inc.

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

For more information, please visit

SOURCE Boehringer Ingelheim

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. One Shot of Gene Therapy Spreads Through Brain in Animal Study
6. Mans Best Friend May Open Door to Understanding Fibrotic Lung Disease in Human and Animal Populations
7. Dog Law Officers Crackdown on Unsatisfactory Kennels Protecting Animals, Consumers
8. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
9. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
10. Researchers Use Magnetism to Target Cells to Animal Arteries
11. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):